ARGX

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 956.06 USD with a low forecast of 780.00 USD and a high forecast of 1146 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

argenx SE revenue for the last quarter amounts to 1.13B USD, increased 96.60 % YoY.

argenx SE. EPS for the last quarter amounts to 5.18 USD, increased 272.66 % YoY.

argenx SE (ARGX) has 1599 emplpoyees as of December 15 2025.

Today ARGX has the market capitalization of 54.05B USD.